In this report the effects of activators of inhibitory muscarinic acetylcholine receptors, adenosine receptors, and prostaglandin El (PGEj) receptors (1-5) on 3':5'-cGMP and 3':5'-cAMP levels of neuroblastoma cells are described. Muscarinic acetylcholine receptors frequently mediate slow, prolonged responses which may be excitatory or inhibitory; in contrast to the nicotinic acetylcholine receptor, which in higher organisms mediates fast excitatory responses. Activation of the inhibitory or excitatory muscarinic acetylcholine receptors of cardiac (6, 7) and smooth muscle (7) results in an increase in cGMP concentration. We find that cGMP levels of neuroblastoma Cell Culture. The following cell lines were used: mouse neuroblastoma C-1300 clones NlE-115 and N18 (8), mouse neuroblastoma X mouse L cell hybrid clone NL1F (9), and rat glioma clone C6BU-1 (10). Neuroblastoma cells were grown in 100 mm petri dishes (Falcon, 55 cm2 surface area) in 15 ml of 90% DMEM-10% fetal-bovine serum (340 mOsm/kg) in a humidified atmosphere of 10% C02-90% air at 370. Hybrid cells were grown in the same medium supplemented with 0.1 mM hypoxanthine, 1 ,uM aminopterin, and 16 ,gM thymidine (HAT). Cells usually were grown to confluency (1 to 3 X 105 cells, 0.1 to 0. Purification of cGMP and cAMP. A rapid method was devised for separating cGMP from cAMP and removing trichloroacetic acid and endogenous interfering compounds from cyclic nucleotide fractions. The supernatant solution of the deproteinized sample in 5% trichloroacetic acid was applied to an ion exchange column (0.7 X 8 cm) of 
increase the concentrations of both cGMP and cAMP. Carbamylcholine, adenosine, and PGEl were added to cells separately and in pairs to determine the effect of one compound on cell responses to another. Reciprocal inhibition, unilateral inhibition, additive, and nonadditive responses were observed with respect to cGMP and cAMP levels when different pairs of receptors were activated simultaneously.
The response of neurons to transmitters frequently can be modified by other species of [transmitter-receptor] interactions; thus, two types of synaptic stimuli may potentiate or inhibit one another. The pharmacology and electrophysiology of such phenomena have been studied extensively but much remains to be learned about the mechanisms which couple the activities of different species of receptors. In part, the difficulty in defining the reactions associated with receptor activation stems from the heterogeneity of neural tissues with regard to cell type. One approach to this problem is to define receptor-mediated responses of relatively homogeneous, clonal neuroblastoma cells which have excitable membranes and respond to chemical and electrical stimuli.
In this report the effects of activators of inhibitory muscarinic acetylcholine receptors, adenosine receptors, and prostaglandin El (PGEj) receptors (1-5) on 3':5'-cGMP and 3':5'-cAMP levels of neuroblastoma cells are described. Muscarinic acetylcholine receptors frequently mediate slow, prolonged responses which may be excitatory or inhibitory; in contrast to the nicotinic acetylcholine receptor, which in higher organisms mediates fast excitatory responses. Activation of the inhibitory or excitatory muscarinic acetylcholine receptors of cardiac (6, 7) and smooth muscle (7) results in an increase in cGMP concentration. We find that cGMP levels of neuroblastoma Cell Culture. The following cell lines were used: mouse neuroblastoma C-1300 clones NlE-115 and N18 (8) , mouse neuroblastoma X mouse L cell hybrid clone NL1F (9) , and rat glioma clone C6BU-1 (10 Purification of cGMP and cAMP. A rapid method was devised for separating cGMP from cAMP and removing trichloroacetic acid and endogenous interfering compounds from cyclic nucleotide fractions. The supernatant solution of the deproteinized sample in 5% trichloroacetic acid was applied to an ion exchange column (0.7 X 8 cm) of (200-400 mesh, hydrogen form, Bio-Rad) previously washed and equilibrated with H20. The column was washed with 2 ml of H20 (eluates discarded) and then with 2 additional ml of H20. The latter eluate (2.0 ml) which contains cGMP was collected on a neutral alumina (WN-3, Sigma) column (0.7 X 3 cm) previously washed with 20 ml of 200 mM sodium acetate, pH 6.2, and then with 10 ml of 5 mM sodium acetate, pH 6.2. The eluate was discarded, and the column was washed with 3 ml of 5 mM sodium acetate buffer, pH 6.2, and then with 1 ml of 200 mM sodium acetate buffer, pH 6.2 (eluates discarded). Then cGMP was eluted with 2 ml of 200 mM sodium acetate, pH 6.2, and portions of the eluate were assayed for cGMP concentration and for recovery. The average recovery of cGMP was about 50%; <1% of the cAMP of the sample was present in the cGMP fraction.
Cyclic AMP fractions were obtained as follows: after cGMP was eluted from the AG50W-X4 column, the column was washed with 2 ml of H20 (eluate discarded) and cAMP was eluted with 3 additional ml of H20. Portions Assay of cGMP and cAMP. The cGMP concentrations of purified alumina column eluates were determined by the radioimmune method of Steiner et al. (11) modified as follows: each 0.5 ml reaction mixture contained 200 mM (in some experiments 140 mM) sodium acetate, pH 6.2 (solution B); 17 fmol of succinyl-cGMP 125I-tyrosine methyl ester (10,000-20,000 cpm); cGMP antibody; and sample (0-20 pmol of cGMP). After incubation (14-18 hr, 3°) each reaction mixture was diluted with 2 ml of solution B at 30; 10 min later the sample was passed through a Millipore filter (0.45 ,um pore size, 25 mm diameter, HAWP 02500) previously rinsed with solution B and washed three times with cold solution B (4 ml each wash). Each filter was placed in a scintillation vial with 1 ml of 2-methoxyethanol; after filters dissolved (0.5-1 hr) 15 ml of Aquasol (New England Nuclear) were added. Radioactivity was determined [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] hr later in a Beckman liquid scintillation counter (3H plus 14C isoset).
Cyclic AMP concentrations of samples purified as described above were determined by the method of Gilman (12) . Each cGMP or cAMP sample was assayed at three or four concentrations. Each value shown corresponds to 100% recovery of cyclic nucleotide and is the mean of duplicate dishes. Protein was determined by a modification of the method of Lowry et al. (13) . RESULTS A rapid method was devised for separating cGMP from cAMP and removing trichloroacetic acid and endogenous factors which interfere with the cGMP assay. The procedure, based upon the Materials and Methods section, is based upon the methods of Salomon, Londos, and Rodbell (14) and White and Zenser (15); cGMP and cAMP are recovered in separate fractions in high yield and in sufficiently high concentration to assay directly without Iyophilization.
One hundred samples can be purified in 2-3 hr.
The effect of carbamylcholine, a relatively stable analog of acetylcholine, upon intracellular cGMP levels of neuroblastoma and other cell lines in the absence of a 3':5'-cyclic nucleotide phosphodiesterase inhibitor is shown in Fig. 1 . Cyclic GMP levels of neuroblastoma clones N18 and N1E- of cGMP in neuroblastoma clones NiE-i15 and N18, neuroblastoma X L cell hybrid clone NL1F, and glioma clone C6BU-1. Cultures were confluent; the average protein content was: 11.5, 16.4, 7.6 and 6.9 mg of protein per 100 mm petri dish for NlE-115, N18, NL1F, and C6BU-1, respectively. A 3':5'-cyclic nucleotide phosphodiesterase inhibitor was not present.
115 rose 40-and 210-fold, respectively, upon incubation with carbamylcholine for 15 sec. and then fell rapidly t-o normal levels (50% decrease in cGMP at 45 sec). Carbamylcholine also elicited a 6-fold increase in the cGMP concentration of the neuroblastoma X L cell hybrid, NL-1F, but had no effect upon cGMP levels of rat glioma clone C6BU-1. Thus, two types of cell lines were found with respect to acetylcholine-receptor-mediated reactions which increase cGMP levels: cell lines which are sensitive to carbamylcholine and a line which is insensitive.
The effect of IBMX, a t3':5'-cyclic nucleotide phosphodiesterase inhibitor, upon the rate of disappearance of intracellular cGMP after stimulation with carbamylcholine is shown in Fig. 2A . In the absence of IBMX, maximum cGMP levels were attained 15 sec after the addition of carbamylcholine, and then rapidly decreased (50% decrease at 45 sec.; Figs. 1 and 2A). In the presence of 0.5 mM IBMX, maximum cGMP levels were attained at 30 sec and cGMP levels then decreased at a slower rate (50% decrease at 3 min).
The effect of IBMX upon carbamylcholine dependent cGMP accumulation also was studied with N1E-115 cells adapted to grow in suspension culture. The assay was modified so that both intra-and extracellular cGMP was determined. As shown in Fig. 2B , carbamylcholine elevated cGMP levels of suspension cells and in the presence of IBMX cGMP levels remained constant during the 10 min incubation period. These results suggest that part of the cGMP formed by cells may be excreted into the medium. Other 3':5'-cyclic nucleotide phosphodiesterase inhibitors such as 4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone (Ro-20-1724) and papaverine were not as effective-as IBMX in maintaining CGMP levels of N18 cells.
The relation between carbamylcholine concentration and CGMP accumulation in Nd E-5in cells is shown in Fig. 3 respectively, upon carbamylcholine-dependent accumulation of cGMP in NlE-115 cells are shown in Fig. 4 . Atropine, at 1 X 10-7 M, inhibited the carbamylcholine-dependent increase in cGMP concentration by 50%; 97% inhibition was obtained with 1 X 10-6 M atropine. In contrast, dtubocurarine did not inhibit appreciably even at 1 X 10-4 M; in fact, in other experiments d-tubocurarine potentiated the carbamylcholine-dependent elevation of cGMP. The inhibition by atropine suggests that the increase in cGMP elicited by carbamylcholine is mediated by the muscarinic acetylcholine receptors.
The effects of PGE1 upon cAMP and cGMP levels of NlE-115 cells are shown in Fig. 5 . Cyclic AMP levels were found to increase markedly upon the addition of 10 IAM PGE1. Unexpectedly, the level of cGMP also increased 6-fold in the presence of PGE1. The maximum concentration of cAMP attained in this experiment was 9-fold higher than that of cGMP; however, in other experiments, the concentration of cGMP dependent on PGE1 increased to 250 pmol Fig. 6A and B, respectively. In the presence of carbamylcholine or PGE1, cGMP levels increased and reached maximum levels within 1 min. The rates of disappearance of cGMP during the subsequent incubation period were linear. In contrast, the basal level of cGMP was reduced approximately 50% in the presence of 0.1 mM adenosine. As shown in Fig. 6B 7). The effect of exposing cells to both carbamylcholine and adenosine upon cGMP arid cAMP levels is shown in Fig. 7A and B, respectively. Adenosine inhibited the carbamylcholine-dependent increase in cGMP concentration 25 and 60% when incubations were 30 and 60 sec, respectively. In Fig. 7B , the effect of carbamylcholine upon the adenosine-dependent increase in cAMP concentration is shown. Carbamylcholine did not inhibit the adenosine-stimulated increase in cAMP during the first 30 see of incubation even though the maximum increase in cGMP concentration evoked by carbamylcholine was achieved at 30 sec. However, during further incubation, carbamylcholine inhibited almost completely the adenosine-dependent elevation in cAMP concentration.
Carbamylcholine and PGE1 added separately increased cGMP levels as indicated by the broken lines in Fig. 7C . The effects of carbamylcholine and PGE1 added simultaneously to cultures were additive or more than additive. However, carbamylcholine inhibited the PGE1-induced increase in cAMP concentration, particularly during the latter part of the incubation period (Fig. 7D) . Thus, carbamylcholine may have a delayed inhibitory effect upon both adenosine-and PGEI-dependent increases in cAMP concentrations. Atropine completely blocked the inhibitory effect of carbamylcholine upon adenosine-or PGEj-dependent increases in cAMP levels (data not shown).
The effect of activating receptors for adenosine and PGE1 separately and simultaneously upon cGMP and cAMP levels is shown in Fig. 7E and F (18) , activates adenylate cyclase activity in homogenates (19) , including those prepared from neuroblastoma X glioma hybrid cells (20) , and inhibits the vasopressin-dependent activation of adenylate cyclase (21) .
